Luminita Pricop

6.2k total citations · 2 hit papers
115 papers, 4.7k citations indexed

About

Luminita Pricop is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Luminita Pricop has authored 115 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Rheumatology, 84 papers in Immunology and 49 papers in Hematology. Recurrent topics in Luminita Pricop's work include Spondyloarthritis Studies and Treatments (74 papers), Psoriasis: Treatment and Pathogenesis (62 papers) and Rheumatoid Arthritis Research and Therapies (49 papers). Luminita Pricop is often cited by papers focused on Spondyloarthritis Studies and Treatments (74 papers), Psoriasis: Treatment and Pathogenesis (62 papers) and Rheumatoid Arthritis Research and Therapies (49 papers). Luminita Pricop collaborates with scholars based in United States, United Kingdom and Switzerland. Luminita Pricop's co-authors include Iain B. McInnes, Philip J. Mease, Shephard Mpofu, Proton Rahman, Désirée van der Heijde, Bruce Kirkham, Jane E. Salmon, Hanno B. Richards, Peter Nash and R. Landewé and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Luminita Pricop

112 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luminita Pricop United States	30	3.5k	2.7k	1.6k	696	531	115	4.7k
Hanno B. Richards United States	35	3.5k 1.0×	3.4k 1.3×	1.5k 0.9×	249 0.4×	544 1.0×	58	5.0k
Daniel Burge United States	14	1.6k 0.5×	2.6k 1.0×	1.5k 0.9×	357 0.5×	305 0.6×	23	3.9k
J. Wollenhaupt Germany	28	2.3k 0.7×	4.1k 1.5×	2.1k 1.3×	257 0.4×	244 0.5×	124	5.2k
Elizabeth C. Hsia United States	34	1.7k 0.5×	3.1k 1.1×	1.6k 1.0×	234 0.3×	135 0.3×	109	3.9k
Hans‐Peter Tony Germany	32	2.1k 0.6×	1.6k 0.6×	803 0.5×	685 1.0×	438 0.8×	151	4.4k
Barbara Finck United States	8	1.3k 0.4×	2.7k 1.0×	1.5k 0.9×	267 0.4×	268 0.5×	17	3.6k
Koichiro Ohmura Japan	35	1.9k 0.5×	1.8k 0.7×	485 0.3×	611 0.9×	872 1.6×	170	4.3k
Carrie Wagner United States	33	1.8k 0.5×	1.9k 0.7×	936 0.6×	714 1.0×	538 1.0×	53	4.8k
Gian Domenico Sebastiani Italy	30	1.9k 0.5×	3.1k 1.2×	560 0.3×	760 1.1×	571 1.1×	109	4.3k
Shephard Mpofu United States	24	2.9k 0.8×	2.9k 1.1×	1.8k 1.1×	71 0.1×	252 0.5×	68	4.1k

Countries citing papers authored by Luminita Pricop

Since Specialization

Citations

This map shows the geographic impact of Luminita Pricop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luminita Pricop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luminita Pricop more than expected).

Fields of papers citing papers by Luminita Pricop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luminita Pricop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luminita Pricop. The network helps show where Luminita Pricop may publish in the future.

Co-authorship network of co-authors of Luminita Pricop

This figure shows the co-authorship network connecting the top 25 collaborators of Luminita Pricop. A scholar is included among the top collaborators of Luminita Pricop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luminita Pricop. Luminita Pricop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kivitz, Alan, Melvin Churchill, Atul Singhal, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. 77(2). 171–179. 1 indexed citations

Gottlieb, Alice B., Atul Deodhar, Iain B. McInnes, et al.. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato Venereologica. 102. adv00698–adv00698. 57 indexed citations

Mease, Philip J., Robert Landewé, Proton Rahman, et al.. (2021). Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 7(2). e001600–e001600. 26 indexed citations

Pournara, Effie, Matthías Kormáksson, Peter Nash, et al.. (2021). Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 7(3). e001845–e001845. 20 indexed citations

Orbai, Ana‐Maria, Iain B. McInnes, Laura C. Coates, et al.. (2019). Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. The Journal of Rheumatology. 47(6). 854–864. 13 indexed citations

Heijde, Désirée van der, Philip J. Mease, Robert Landewé, et al.. (2019). Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Lara D. Veeken. 59(6). 1325–1334. 45 indexed citations

McInnes, Iain B., Dafna D. Gladman, Atul Deodhar, et al.. (2019). Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis. Queensland's institutional digital repository (The University of Queensland). 71. 1 indexed citations

Coates, Laura C., Johan K. Wallman, Dennis McGonagle, et al.. (2019). Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research & Therapy. 21(1). 266–266. 13 indexed citations

McInnes, Iain B., Alan Kivitz, Peter Nash, et al.. (2018). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: LONG-TERM (4-YEAR) DATA FROM A PHASE 3 STUDY. JCR Journal of Clinical Rheumatology. 25. 1 indexed citations

10.

Coates, Laura C., Tore K Kvien, Peter Nash, et al.. (2017). AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). Annals of the Rheumatic Diseases. 76. 1326–1326. 2 indexed citations

11.

Mease, Philip J., Iain B. McInnes, Kristian Reich, et al.. (2017). Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses. Queensland's institutional digital repository (The University of Queensland). 69. 2149–2149. 1 indexed citations

12.

McInnes, Iain B., B. W. Kirkham, Arthur Kavanaugh, et al.. (2015). Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Journal of Investigative Dermatology. 135. 2 indexed citations

13.

Mease, Philip J., Iain B. McInnes, Bruce Kirkham, et al.. (2015). Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 67. 2576–2578. 4 indexed citations

14.

Gottlieb, Alice B., Philip Mease, Iain B. McInnes, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 66. 12 indexed citations

15.

Landewé, Robert, Iain B. McInnes, Philip G. Conaghan, et al.. (2014). Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 42–43. 16 indexed citations

16.

McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. Data Archiving and Networked Services (DANS). 66(12). 3529–3529. 19 indexed citations

17.

Pricop, Luminita, et al.. (2011). Recent contributions to the scientific substantiation of the gene theory of sexuality in Galinaceae.. 3(1). 26–37. 1 indexed citations

18.

Jacob, Noam, Haitao Yang, Luminita Pricop, et al.. (2009). Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway. The Journal of Immunology. 182(4). 2532–2541. 81 indexed citations

19.

Liu, Yi, Xiaoni Gao, Emi Masuda, et al.. (2006). Regulated Expression of FcγR in Human Dendritic Cells Controls Cross-Presentation of Antigen-Antibody Complexes. The Journal of Immunology. 177(12). 8440–8447. 55 indexed citations

20.

Pricop, Luminita, Patricia Redecha, Jean‐Luc Teillaud, et al.. (2001). Differential Modulation of Stimulatory and Inhibitory Fcγ Receptors on Human Monocytes by Th1 and Th2 Cytokines. The Journal of Immunology. 166(1). 531–537. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact